Schizophrenia trials in Italy

In Italy 11 Also abroad 491

9 of 11 trials · From ClinicalTrials.gov and EU CTIS (euclinicaltrials.eu), checked 15 November 2026. Ask the study team whether a trial fits you.

Phase 2Taking people
A Study to Assess the Efficacy and Safety of ML-007C-MA for the Treatment of Alzheimer's Disease Psychosis
Where
Rome, Tricase
Age
55 years to 90 years
People
300 worldwide
Run by
MapLight Therapeutics
See details and how to joinNCT06887192 · EU 2024-519820-26-00
Phase 2Not yet taking people in Italy
An Open-Label Study of ML-007C-MA in Adults With Alzheimer's Disease Psychosis
Where
Rome, Tricase
Age
55 years to 91 years
People
210 worldwide
Run by
MapLight Therapeutics
See details and how to joinNCT07459660 · EU 2025-521757-16-00
Phase 2Taking people
A Study to Assess the Efficacy and Safety of ITI-1284 in the Treatment of Psychosis Associated With Alzheimer's Disease
Where
Arzignano, Brescia, Cefalù, Tricase
Age
55 years and over
People
370 worldwide
Run by
Intra-Cellular Therapies, Inc.
See details and how to joinNCT06540833
Phase 3Taking people
A Study to Evaluate KarXT as a Treatment for Psychosis Associated With Alzheimer's Disease (ADEPT-4)
Where
Brescia, Milan, Rome
Age
55 years to 90 years
People
406 worldwide
Run by
Karuna Therapeutics, Inc., a Bristol Myers Squibb company
See details and how to joinNCT06585787 · EU 2024-516363-92-00
Phase 3Not yet taking people in Italy
Stratification and Treatment in Early Psychosis Study - ENHANCE
Where
Naples
Age
16 years to 40 years
People
250 worldwide
Run by
University of Oxford
See details and how to joinNCT06778564 · EU 2025-521929-32-00
Phase 3Not yet taking people in Italy
Stratification and Treatment in Early Psychosis Study -ASSIST
Where
Naples
Age
16 years to 50 years
People
250 worldwide
Run by
University of Oxford
See details and how to joinNCT07326124
Phase 3Not yet taking people in Italy
Stratification and Treatment in Early Psychosis Study - PROMOTE
Where
Bari, Naples, Pavia, Roma
Age
12 years to 35 years
People
586 worldwide
Run by
University of Oxford
See details and how to joinNCT07434973
Phase 4Active, not recruiting
The Effect of a Six Week Intensified Pharmacological Treatment for Schizophrenia Compared to Treatment as Usual in Subjects Who Had a First-time Treatment Failure on Their First-line Treatment.
Where
Brescia, Cagliari, Naples, Turin
Age
18 years to 70 years
People
418 worldwide
Run by
Dr. Inge Winter
See details and how to joinNCT05958875 · EU 2023-506602-39-00
Phase 1Not yet taking people in Italy
A Randomized, Multiple-Dose, Open-Label, Parallel-Group Study to Evaluate the Pharmacokinetic Profiles of LY03010 and the Relative Bioavailability at Steady-State of LY03010 versus XEPLION® in Patients with Schizophrenia
Where
Bourgas
Age
18 years and over
People
170 worldwide
Run by
Geneora Pharma (Shijiazhuang) Co. Ltd.
See details and how to join2023-508981-13-00